Fri, October 30, 2020
Thu, October 29, 2020
Wed, October 28, 2020
Tue, October 27, 2020
Mon, October 26, 2020
Fri, October 23, 2020

Colin Bristow Initiated (SRPT) at Strong Buy and Held Target at $212 on, Oct 28th, 2020


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. buy-and-held-target-at-212-on-oct-28th-2020.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Colin Bristow of UBS, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $212 on, Oct 28th, 2020.

Colin has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Martin Auster of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $167 on, Thursday, August 20th, 2020


These are the ratings of the 4 analyists that currently disagree with Colin


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $221 on, Monday, August 31st, 2020
  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $200 on, Tuesday, August 25th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020

Publication Contributing Sources